ArticleFrontiers in oncology2022

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Graziana Digiacomo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.